Paul Tudor Jones's NTLA Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 189,076 shares of Intellia Therapeutics, Inc. (NTLA) worth $1.7 M, representing 0.00% of the portfolio. First purchased in 2021-Q2, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in NTLA, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 189,076 shares. Largest reduction occurred in Q3 2025, reducing 114,964 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Intellia Therapeutics (NTLA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Intellia Therapeutics (NTLA) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +189,076 | New Buy | 189,076 | $8.99 |
| Q3 2025 | -114,964 | Sold Out | 0 | $0.00 |
| Q2 2025 | +46,687 | Add 68.38% | 114,964 | $9.38 |
| Q1 2025 | +68,277 | New Buy | 68,277 | $7.11 |
| Q4 2024 | -24,803 | Sold Out | 0 | $0.00 |
| Q3 2024 | -36,980 | Reduce 59.85% | 24,803 | $20.55 |
| Q2 2024 | +14,308 | Add 30.14% | 61,783 | $22.38 |
| Q1 2024 | +47,475 | New Buy | 47,475 | $27.51 |
| Q4 2023 | -7,638 | Sold Out | 0 | $0.00 |
| Q3 2023 | +7,638 | New Buy | 7,638 | $31.62 |
| Q1 2023 | -44,902 | Sold Out | 0 | $0.00 |
| Q4 2022 | +13,817 | Add 44.45% | 44,902 | $0.03 |
| Q3 2022 | +31,085 | New Buy | 31,085 | $55.98 |
| Q2 2022 | -19,273 | Sold Out | 0 | $0.00 |
| Q1 2022 | +19,273 | New Buy | 19,273 | $72.69 |
| Q4 2021 | -12,109 | Sold Out | 0 | $0.00 |
| Q3 2021 | +4,654 | Add 62.43% | 12,109 | $134.12 |
| Q2 2021 | +7,455 | New Buy | 7,455 | $161.90 |
Paul Tudor Jones's Intellia Therapeutics Investment FAQs
Paul Tudor Jones first purchased Intellia Therapeutics, Inc. (NTLA) in Q2 2021, acquiring 7,455 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Intellia Therapeutics, Inc. (NTLA) for 18 quarters since Q2 2021.
Paul Tudor Jones's largest addition to Intellia Therapeutics, Inc. (NTLA) was in Q4 2025, adding 189,076 shares worth $1.7 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 189,076 shares of Intellia Therapeutics, Inc. (NTLA), valued at approximately $1.7 M.
As of the Q4 2025 filing, Intellia Therapeutics, Inc. (NTLA) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Intellia Therapeutics, Inc. (NTLA) was 189,076 shares, as reported at the end of Q4 2025.